Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addition to genetic mutations, epigenetic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ververis, Katherine, Hiong, Alison, Karagiannis, Tom C, Licciardi, Paul V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584656/
https://www.ncbi.nlm.nih.gov/pubmed/23459471
http://dx.doi.org/10.2147/BTT.S29965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584656/
https://www.ncbi.nlm.nih.gov/pubmed/23459471
http://dx.doi.org/10.2147/BTT.S29965

Ejemplares similares